On March 18, 2026, Spectral AI, Inc. (Nasdaq: MDAI) announced that it has been awarded $31.7 million in funding from the Biomedical Advanced Research and Development Authority (BARDA). This funding aims to accelerate the development of the company's DeepView System, an AI-driven technology designed for burn wound imaging. The funding is part of a larger contract with BARDA, which has a total value of up to $150 million. Spectral AI has also committed an additional $9.7 million towards the development costs associated with enhancing the DeepView System's features.

The DeepView System is intended for use in emergency departments, trauma centers, and burn centers, providing critical diagnostic support for physicians in assessing burn wounds. The technology is particularly vital in mass casualty incidents, where rapid and accurate assessment can significantly impact patient outcomes. Vincent Capone, CEO of Spectral AI, expressed gratitude for BARDA's continued support, emphasizing the importance of the DeepView System in improving clinical decision-making in burn care.

This funding is non-dilutive, meaning it will not affect the ownership structure of the company, which is a positive aspect for current shareholders. The company is currently awaiting market authorization from the U.S. Food and Drug Administration (FDA) for the DeepView System, which could further enhance its market position and operational capabilities.

Overall, this funding represents a significant step forward for Spectral AI, reinforcing its commitment to innovation in medical diagnostics and potentially leading to improved healthcare outcomes for burn patients.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.